DICLOFENAC POTASSIUM 50MG + SERRATIOPEPTIDASE 10MG TABLETS are a combination oral solid dosage form containing Diclofenac Potassium and Serratiopeptidase as active pharmaceutical ingredients. The development of a combination tablet calls for extra attention to the physicochemical properties of the component active ingredients, especially where one of the ingredients (Serratiopeptidase) is an enzyme-based pharmaceutical ingredient that may need to be handled under specific processing conditions. Homogeneous blending, appropriate compression parameters and effective packaging all have a role in ensuring finished-product quality. For a company planning to grow a PCD Pharma Franchise range, this combination tablet can be used as part of a professionally managed portfolio of pharmaceutical formulations.
Each tablet contains Diclofenac Potassium 50 mg and Serratiopeptidase 10 mg according to the composition table. The active pharmaceutical ingredients, while providing a well-defined combination profile, have individual formulation characteristics that should be carefully assessed during preformulation workup before large-scale manufacturing.
The finished-tablet excipient system may include chosen diluents, binders, disintegrants, glidants and lubricants depending on the designed final formulation. Selection will be directed by excipient compatibility with active pharmaceutical ingredients and their functional properties, including powder flow, compression properties and tablet disintegration and dissolution.
Preformulation work may encompass particle size analysis, bulk density and flow rate, moisture sensitivity studies and compatibility tests with selected excipients. For an enzyme-based pharmaceutical ingredient, consideration may also be given to environmental and process parameters that affect enzyme activity and stability.
The design of the finished-tablet formulation will, as always, prioritize a system that can reliably provide the right tableting performance combined with minimum stability risks.
Serratiopeptidase is a pharmaceutical ingredient based on enzyme technology, requiring controlled handling considerations. The process equipment and conditions will be selected in line with quality and stability data as they become available.
During production, the enzyme may be protected from unnecessary exposure to unwarranted environmental conditions by controlled material handling and process conditions. The points of addition of the active pharmaceutical ingredients and the sequence of blending steps may be optimized for uniformity without imparting excessive stresses on the enzyme component.
Component physico-chemical differences may be notable and bulk powder assessment, flow and blend uniformity may be performed to select suitable premixing steps. Product flowmay influence processing choices including compression weight range, core versus incremental fill and the speed of production.
The consistency of blend at key points in the process may be assessed periodically. The blending method should aim for reproducibility and the blending time or intensity should not be excessive, avoiding physical degradation while ensuring homogeneity.
Following precompressed blend quality assurance checks, the batch material may be transferred to compression equipment. The compression parameters can be optimized for formulation flow characteristics and material compression index.
Parameters such as dwell time and compression speed (or pressure) can influence the physical properties of the compression and therefore the bulk flow, compression efficiency and hardness.
Sample tablets can be obtained during the compression run and assessed in comparison to a target profile for weight and appearance. Adjustments in equipment parameters may be made to optimize consistency.
The production of the formulation can include coating, although the process parameters for coating are not described here. If coating is applied, parameters such as flow rate, spray rate, drying temperature, coater speed and coating uniformity can be validated and controlled.
Quality control testing of DICLOFENAC POTASSIUM 50MG + SERRATIOPEPTIDASE 10MG TABLETS involves both uniformity testing in the finished dosage form, and component-specific controls for the active ingredients. Appropriate suitable analytical methods can be used to measure the bulk component identity and strength.
Diclofenac Potassium may be checked using a validated assay method, while for Serratiopeptidase an assay or enzymology-based method may be prescribed in the quality specification.
Physical testing will include appearance, diameter, average weight and weight variation, tablet friability, hardness and disintegration, as well as specific dissolution test procedures as determined during product development. The assay of active component in tablet material will also be checked.
Component uniformity and other identity/strength testing may be performed on the finished dosage form. Where relevant, additional testing to evaluate product stability may be included.
The physical stability of a formulation containing an enzyme-based active pharmaceutical ingredient as well as the smaller nonenzyme component may be a matter requiring study over the product shelf life. Physical, chemical, enzymic and other component-related stability parameters will be evaluated.
The packaging system will need to be selected for the product's physical and chemical stability profile. If needed, an overwrap or packing under inert gas may be used. A protection coating may be applied as indicated by stability data.
In-use stability testing may be employed to identify potential zones for product degradation or deterioration. The most sensitive properties may be monitored over a simulated shelf life. The packaging system will be used to protect the finished dosage form against environmental hazards that are measured.
Together with other combination formulations, DICLOFENAC POTASSIUM 50MG + SERRATIOPEPTIDASE 10MG TABLETS contribute to a well-stocked portfolio of combination formulations which should have well-documented stability, identity and strength. Packaging selection can be employed to maximize the commercial shelf life. Further description of components and active pharmaceutical ingredients should be distributed with product literature and artwork to ensure clarity of identification.
In a PCD Pharma Franchise range, this formulation can be marketed with appropriate pack sizes, manufacturer company details, logos and a clear product composition and strength. The differentiator of the enzyme-containing component may require additional focus upon its controlled manufacturing as part of combination therapy.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech